

CITATION REPORT

List of articles citing

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

DOI: 10.1016/j.cell.2020.05.025
Cell, 2020, 182, 73-84.e16.

Source: <https://exaly.com/paper-pdf/76593366/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1025	Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?. 2020 , 41, 851-853		5
1024	Therapeutic Potential of B-1a Cells in COVID-19. 2020 , 54, 586-594		10
1023	Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects. 2020 , 131, 110748		14
1022	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020 , 183, 169-184.e13	56.2	221
1021	High Potency of a Bivalent Human V Domain in SARS-CoV-2 Animal Models. <i>Cell</i> , 2020 , 183, 429-441.e16	56.2	67
1020	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. 2020 , 15, 3699-3715		113
1019	Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation. 2020 , 169, 112572		32
1018	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. 2020 , 11, 2016		10
1017	Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019. 2020 , 262, 118496		3
1016	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. <i>Cell</i> , 2020 , 183, 1058-1069.e19	56.2	182
1015	Beyond bulk single-chain sequencing: Getting at the whole receptor. 2020 , 24, 93-99		6
1014	Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. 2020 , 10, 17806		27
1013	A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19. 2020 , 2, 1-8		5
1012	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. 2020 , 33, 108322		35
1011	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. 2020 , 33, 108274		107
1010	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. 2020 , 370, 1110-1115		330
1009	Mining the Antibody Repertoire for Solutions to SARS-CoV-2. 2020 , 28, 499-501		2

1008	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. 2020 , 41, 1006-1022	46
1007	A systematic review of SARS-CoV-2 vaccine candidates. 2020 , 5, 237	257
1006	A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers. 2020 , 11, 12157-12164	42
1005	A materials-science perspective on tackling COVID-19. 2020 , 1-14	123
1004	Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology. 2020 , 86, 1-7	11
1003	Immune Literacy: Reading, Writing, and Editing Adaptive Immunity. 2020 , 23, 101519	8
1002	Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. 2020 , 117, 25254-25262	116
1001	Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine. 2020 , 6, 1341-1347	2
1000	Methods for sequence and structural analysis of B and T cell receptor repertoires. 2020 , 18, 2000-2011	8
999	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. 2020 , 26, 1428-1434	223
998	Structural basis of a shared antibody response to SARS-CoV-2. 2020 , 369, 1119-1123	338
997	Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. <i>Cell</i> , 2020 , 182, 843-854.e12	56.2 185
996	The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. <i>Cell</i> , 2020 , 182, 1284-1294.e8	56.2 185
995	Current and Future Direct-Acting Antivirals Against COVID-19. 2020 , 11, 587944	10
994	Global SNP analysis of 11,183 SARS-CoV-2 strains reveals high genetic diversity. 2021 , 68, 3288-3304	29
993	Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. 2020 , 18, 3774-3787	11
992	SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. 2020 , 10, 587269	199
991	Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody. 2021 , 12, 751-755	21

990	Monoclonal Antibodies B38 and H4 Produced in Neutralize SARS-CoV-2. 2020 , 11, 589995	24
989	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. 2020 , 53, 1272-1280.e5	112
988	Microfluidic devices for the detection of viruses: aspects of emergency fabrication during the COVID-19 pandemic and other outbreaks. 2020 , 476, 20200398	16
987	Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19. 2020 , 2, 1-14	4
986	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. 2020 , 7, 605236	60
985	Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. 2020 , 8, 1539	10
984	Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis. 2020 , 11, 595970	4
983	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. 2020 , 588, 682-687	651
982	Non-Receptor-Mediated Lipid Membrane Permeabilization by the SARS-CoV-2 Spike Protein S1 Subunit. 2020 , 12, 55649-55658	12
981	Computational Insights into the Conformational Accessibility and Binding Strength of SARS-CoV-2 Spike Protein to Human Angiotensin-Converting Enzyme 2. 2020 , 11, 10482-10488	16
980	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. 2020 , 11, 588409	11
979	A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds. 2020 , 11, 573526	20
978	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. 2020 , 8,	8
977	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. 2020 , 329	4
976	Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients. 2020 , 40, 618-624	30
975	COVID-19 spread in the UK: the end of the beginning?. 2020 , 396, 587-590	38
974	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. 2020 , 13, 957-975	5
973	Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. 2020 , 55, 2556-2564	25

972	Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks. <i>Cell</i> , 2020 , 182, 7-9	56.2
971	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. 2020 , 41, 815-829	66
970	Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. 2021 , 73, e531-e539	125
969	Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. 2020 , 3, 813-834	17
968	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. <i>Cell</i> , 2020 , 182, 1295-1310.e20	56.2 935
967	Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. 2020 , 584, 450-456	848
966	Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. 2020 , 5, 156	82
965	Potently neutralizing and protective human antibodies against SARS-CoV-2. 2020 , 584, 443-449	609
964	Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. 2020 , 117, 29832-29838	57
963	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. 2020 , 5, 1598-1607	667
962	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020 , 217,	289
961	Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Nanogel as a Pro-Antigen Strategy with Enhanced Protective Immune Responses. 2020 , 16, e2004237	6
960	Probing infectious disease by single-cell RNA sequencing: Progresses and perspectives. 2020 , 18, 2962-2971	8
959	The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. 2020 , 9,	29
958	Sensitivity and specificity of SARS-CoV-2 S1 subunit in COVID-19 serology assays. 2020 , 6, 75	19
957	Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. 2020 , 11, 4400	105
956	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. 2020 , 5, 180	151
955	An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. 2020 , 11, 4420	151

954	The Answer Lies in the Energy: How Simple Atomistic Molecular Dynamics Simulations May Hold the Key to Epitope Prediction on the Fully Glycosylated SARS-CoV-2 Spike Protein. 2020 , 11, 8084-8093	24
953	Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. 2020 , 205, 2437-2446	48
952	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. 2020 , 5, 212	59
951	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. <i>Cell</i> , 2020 , 183, 1013-1023.e13	56.2 145
950	Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2. 2020 , 28, 516-525.e5	121
949	Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. 2021 , 25, 415-421	19
948	Antibody-like proteins that capture and neutralize SARS-CoV-2. 2020 , 6,	12
947	Deep Mining of Human Antibody Repertoires: Concepts, Methodologies, and Applications. 2020 , 4, 2000451	1
946	SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health. 2020 , 192, E973-E979	35
945	Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?. 2020 , 9,	2
944	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. 2020 , 11, 4303	94
943	A Simple Algorithm for Return to Workplace Employer Antibody Testing. 2020 , 23, 346-349	
942	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. 2020 , 12,	32
941	Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. 2020 , 17, 1095-1097	91
940	Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice. 2020 , 12,	9
939	Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. 2020 , 5, 1185-1191	329
938	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma. 2020 , 15, e0238089	41
937	The global response to the COVID-19 pandemic: how have immunology societies contributed?. 2020 , 20, 594-602	10

936	Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein. 2020 , 5, 81	11
935	Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). 2020 , 98, 1369-1383	19
934	A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment. 2020 , 7, 186	15
933	Animal and translational models of SARS-CoV-2 infection and COVID-19. 2020 , 13, 877-891	106
932	The Application of Single-Cell RNA Sequencing in Vaccinology. 2020 , 2020, 8624963	8
931	Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer. 2020 , 154, 620-626	21
930	Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2. 2020 , 21,	4
929	Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. 2020 , 3, 246-256	14
928	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). 2020 , 11, 571481	28
927	A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters. 2020 , 11, 614256	25
926	May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?. 2020 , 18, 489	4
925	Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. 2020 , 12, 1854149	79
924	Neutralizing antibodies for the treatment of COVID-19. 2020 , 4, 1134-1139	52
923	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. 2020 , 9,	11
922	Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. 2020 , 370, 1479-1484	138
921	Man-Specific, GalNAc/T/Tn-Specific and Neu5Ac-Specific Seaweed Lectins as Glycan Probes for the SARS-CoV-2 (COVID-19) Coronavirus. 2020 , 18,	10
920	Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. 2020 , 11, 9781-9787	13
919	Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. 2020 , 11, 5588	73

918	An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. 2020 , 370, 1473-1479	166
917	Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping. 2020 , 2020, 9465398	18
916	COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. 2020 , 8,	27
915	A Single Human V-gene Allows for a Broad-Spectrum Antibody Response Targeting Bacterial Lipopolysaccharides in the Blood. 2020 , 32, 108065	11
914	Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo. 2020 , 6, 76	44
913	Decoding SARS-CoV-2 Transmission and Evolution and Ramifications for COVID-19 Diagnosis, Vaccine, and Medicine. 2020 , 60, 5853-5865	57
912	Passive antibody therapy in COVID-19. 2020 , 20, 401-403	64
911	Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. 2020 , 369, 1014-1018	794
910	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. 2020 , 369, 650-655	854
909	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020 , 182, 828-842.e16	56.2 485
908	Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic. 2020 , 44, 102249	14
907	Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. 2020 , 369, 1010-1014	719
906	A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. 2020 , 27, 125-136.e7	338
905	Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy. 2020 , 11, 1576	20
904	COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. 2020 , 94,	63
903	Gene signatures of SARS-CoV/SARS-CoV-2-infected ferret lungs in short- and long-term models. 2020 , 85, 104438	32
902	Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. 2020 , 32, 107918	107
901	Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery. 2020 , 26, 1703-1705	40

900	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. 2020 , 205, 915-922	126
899	Molecular identification of <i>Cryptococcus gattii</i> from cerebrospinal fluid using single-cell sequencing: A case study. 2020 , 81, 634-638	3
898	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. 2020 , 26, 1422-1427	283
897	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. 2020 , 28, 486-496.e6	116
896	Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. 2020 , 257, 118056	89
895	High-dimensional single-cell analysis reveals the immune characteristics of COVID-19. 2021 , 320, L84-L98	9
894	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. 2021 , 40, 5-53	13
893	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. 2021 , 60, 9789-9802	23
892	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. 2021 , 133, 9873-9886	4
891	DockCoV2: a drug database against SARS-CoV-2. 2021 , 49, D1152-D1159	17
890	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. 2021 , 137, 1365-1376	26
889	Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles. 2020 , 12, 987-990	13
888	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. 2021 , 538, 192-203	93
887	Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins. 2020 , 100058	62
886	Review of COVID-19 Antibody Therapies. 2021 , 50, 1-30	15
885	Why Does the Novel Coronavirus Spike Protein Interact so Strongly with the Human ACE2? A Thermodynamic Answer. 2021 , 22, 865-875	21
884	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. 2021 , 23, 101-110	11
883	Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. 2021 , 44, 7-17	20

882	A review of COVID-19 biomarkers and drug targets: resources and tools. 2021 , 22, 701-713	12
881	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. 2021 , 538, 187-191	39
880	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. 2021 , 106, 104488	14
879	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. 2021 , 29, 44-57.e9	525
878	Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. 2021 , 169, 100-117	25
877	Recent Insights into Emerging Coronavirus: SARS-CoV-2. 2021 , 7, 1369-1388	13
876	COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. 2021 , 16, 25-35	4
875	Enhanced SARS-CoV-2 neutralization by dimeric IgA. 2021 , 13,	178
874	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. 2021 , 20, 139-153	6
873	Dynamic anti-spike protein antibody profiles in COVID-19 patients. 2021 , 103, 540-548	11
872	Immunologic Testing for SARS-CoV-2 Infection from the Antigen Perspective. 2021 , 59,	34
871	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. 2021 , 26, 311-329	0
870	Viral targets for vaccines against COVID-19. 2021 , 21, 73-82	402
869	Neutralizing antibodies targeting SARS-CoV-2 spike protein. 2020 , 50, 102125	35
868	The scientific and ethical feasibility of immunity passports. 2021 , 21, e58-e63	49
867	Coronavirus biology and replication: implications for SARS-CoV-2. 2021 , 19, 155-170	830
866	Association of an IGHV3-66 gene variant with Kawasaki disease. 2021 , 66, 475-489	9
865	Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. 2021 , 17, 113-121	42

864	Modeling in the Time of COVID-19: Statistical and Rule-based Mesoscale Models. 2021 , 27, 722-732	7
863	Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering. 2021 , 19, 518-529	9
862	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. 2021 , 10, 1589-1597	11
861	Hybridoma technology: is it still useful?. 2021 , 2, 32-40	7
860	Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment.	35
859	Synthetic nanobody-SARS-CoV-2 receptor-binding domain structures identify distinct epitopes. 2021 ,	7
858	The role and uses of antibodies in COVID-19 infections: a living review. 2021 , 2, iqab003	5
857	Impact of New Variants on SAR-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions.	1
856	A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. 2021 , 13, 1930636	7
855	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. 2021 , 12, 324	32
854	Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. 2021 , 182, 417-424	7
853	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. 2021 , 12, 469	74
852	Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. 2021 , 12, 6929-6948	37
851	Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. 2020 , 11, 618685	29
850	Binding affinity and mechanisms of SARS-CoV-2 variants. 2021 , 19, 4184-4191	5
849	Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. 2021 ,	28
848	Evolution of antibody immunity to SARS-CoV-2. 2021 , 591, 639-644	652
847	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. 2021 , 28, 9	52

846	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. 2021 ,	5
845	Passive Immunity Should and Will Work for COVID-19 for Some Patients. 2021 , 3, 47-68	1
844	Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein.	
843	Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development. 2021 , 2021, 8870425	6
842	The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. 2021 ,	27
841	Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. 2021 , 12, 264	41
840	SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. 2021 , 4, 129	46
839	50 Years of structural immunology. 2021 , 296, 100745	3
838	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. 2021 , 12, 542	86
837	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. 2021 , 13,	30
836	Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. 2021 ,	14
835	Dual-Antigen System Allows Elimination of False Positive Results in COVID-19 Serological Testing. 2021 , 11,	5
834	Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. 2021 , 13, 1893426	7
833	Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. 2021 , 10, 1097-1111	6
832	Miniaturized single-cell technologies for monoclonal antibody discovery. 2021 , 21, 3627-3654	2
831	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. 2021 , 12, 288	108
830	Stereotypic neutralizing V antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals. 2021 , 13,	36
829	Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.	1

828	SARS-CoV-2 receptor binding mutations and antibody mediated immunity.	3
827	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat RBD of SARS-CoV-2 spike protein protects mice against COVID-19.	
826	The humoral response to BK polyomavirus in kidney transplant recipients is dominated by IgM antibodies that use a distinct repertoire compared to IgG against the same antigen.	
825	Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2.	
824	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.	3
823	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. 2021 , 12, 776	26
822	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. 2020 , 11, 583914	4
821	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. 2021 ,	5
820	Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library. 2021 , 30, 716-727	8
819	A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques.	1
818	Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.	2
817	Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. 2021 , 2, 100080	20
816	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. 2021 ,	26
815	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. 2021 , 17, e1009352	24
814	Graphene Sheets with Defined Dual Functionalities for the Strong SARS-CoV-2 Interactions. 2021 , 17, e2007091	23
813	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 2021 ,	10
812	Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.	5
811	Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. 2021 , 17, e1009165	20

810	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. 2021 , 371, 735-741	130
809	Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. 2021 ,	5
808	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.	7
807	COVID-19 mRNA vaccines. 2021 , 48, 107-114	24
806	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. 2021 , 34, 108699	54
805	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. 2021 , 592, 616-622	730
804	IMMUNO-COV2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.	0
803	Nanotraps for the containment and clearance of SARS-CoV-2.	1
802	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. 2021 ,	3
801	A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. 2021 ,	47
800	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. 2021 , 6,	70
799	Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library. 2021 , 22,	5
798	Adjunct Therapy for CD4 T-Cell Recovery, Inflammation and Immune Activation in People Living With HIV: A Systematic Review and Meta-Analysis. 2021 , 12, 632119	2
797	Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2.	3
796	Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. 2021 , 12, 897	36
795	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies : Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations.	1
794	Development and deployment of COVID-19 vaccines for those most vulnerable. 2021 , 13,	32
793	SARS-CoV-2 virus: Vaccines in development. 2021 , 1, 131-138	6

792	A spatial and cellular distribution of neurotropic virus infection in the mouse brain revealed by fMOST and single cell RNA-seq.	
791	Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. 2021 , 9,	1
790	Insights into biological therapeutic strategies for COVID-19. 2021 , 1, 166-178	2
789	Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain. 2021 ,	19
788	A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. 2021 , 2, 101-113	33
787	Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. 2021 ,	4
786	Modelling the population-level protection conferred by COVID-19 vaccination.	2
785	A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes. 2021 ,	26
784	Single-Cell Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets and Discrete Development Pathways. 2021 , 12, 602539	17
783	What do we know about the antibody responses to SARS-CoV-2?. 2021 , 226, 152054	8
782	Rationalizing Random Walks: Replicating Protective Antibody Trajectories. 2021 , 42, 186-197	2
781	All-Atom Simulations and Free-Energy Calculations of Antibodies Bound to the Spike Protein of SARS-CoV-2: The Binding Strength and Multivalent Hydrogen-Bond Interactions. 2021 , 4, 2100012	1
780	Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells.	2
779	Structural modeling of the SARS-CoV-2 Spike/human ACE2 complex interface can identify high-affinity variants associated with increased transmissibility.	1
778	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. 2021 ,	3
777	Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. 2021 , 12, 614436	10
776	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. 2021 , 7,	32
775	Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. 2021 , 60, 10266-10272	44

774	Nicotinic cholinergic system and COVID-19: In silico identification of interactions between $\alpha 7$ nicotinic acetylcholine receptor and the cryptic epitopes of SARS-CoV and SARS-CoV-2 Spike glycoproteins. 2021 , 149, 112009	19
773	Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. 2021 , 34, 108915	56
772	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. 2021 , 27, 717-726	497
771	A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2. 2021 , 17, e1009328	17
770	Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma. 2021 , 11, 5558	9
769	A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2. 2021 , 12, 653189	11
768	SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage.	8
767	Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. 2021 , 9, 15	11
766	High-throughput approaches of diagnosis and therapies for COVID-19: antibody panels, proteomics and metabolomics. 2021 , 3, FDD55	6
765	The Future of Blood Testing Is the Immunome. 2021 , 12, 626793	10
764	Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. 2021 , 133, 10354-10360	10
763	Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. 2021 , 118, 102596	11
762	Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein. 2021 , 7, e06564	13
761	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. 2021 , 372,	217
760	Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope. 2021 , 13,	11
759	The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD. 2021 ,	17
758	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. 2021 , 12, 1577	28
757	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021 , 184, 1188-1200.e19	56.2 68

756	SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. 2021 , 12, 1813	109
755	Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients. 2021 , 104, 661-669	10
754	The next-generation coronavirus diagnostic techniques with particular emphasis on the SARS-CoV-2. 2021 , 93, 4219-4241	5
753	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. 2021 ,	24
752	Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2. 2021 , 6,	5
751	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. 2021 , 16, 398-411	9
750	COVID-19 dominant D614G mutation in the SARS-CoV-2 spike protein desensitizes its temperature-dependent denaturation.	4
749	Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants.	7
748	Drug discovery and development targeting the life cycle of SARS-CoV-2. 2021 , 1, 151-165	3
747	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. 2021 , 31, 517-525	20
746	The effect of spike mutations on SARS-CoV-2 neutralization. 2021 , 34, 108890	113
745	Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane. 2021 , 17, 2479-2487	26
744	The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity. 2021 , 6, 113	15
743	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. 2021 ,	27
742	In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect. 2021 , 22, 163	12
741	A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. 2021 , 59,	52
740	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay.	2
739	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. 2021 , 118,	40

738	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. 2021 ,	2
737	Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.	1
736	Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity. 2021 ,	1
735	Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production. 2021 , 8, 629873	19
734	Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. 2021 , 35, 108950	38
733	Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review: 31. 2021 , 178, 3359-3372	8
732	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. 2021 , 29, 551-563.e5	42
731	NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. 2021 , 22, e52325	12
730	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. <i>Cell</i> , 2021 , 184, 2362-2371.e9	197
729	Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections. 2021 , 15, 644-648	
728	Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase. 2021 , 16, 881-895	2
727	Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine. 2021 , 12, 818-823	5
726	Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. 2021 , 2, 100253	18
725	Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. 2021 , 125, 4596-4619	16
724	Neutralizing Antibody Therapeutics for COVID-19. 2021 , 13,	44
723	A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. 2021 , 10, 874-884	2
722	SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques. 2021 ,	1
721	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. 2021 , 17, e1009064	7

720	Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. 2021 , 18, 87		15
719	A potentially neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope. 2021 ,		6
718	COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. <i>Cell</i> , 2021 , 184, 1895-1913.e19		19
717	Quantitative Analysis of Conserved Sites on the SARS-CoV-2 Receptor-Binding Domain to Promote Development of Universal SARS-Like Coronavirus Vaccines.		1
716	Structural insights into SARS-CoV-2 infection and therapeutics development. 2021 , 52, 102219		3
715	Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study. 2021 , 10, 53		5
714	Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concern.		1
713	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. 2021 , 7, e06836		3
712	A Perspective on COVID-19 Management. 2021 , 10,		3
711	Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum. 2021 , 7, 2362-2369		10
710	SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. 2021 , 2, 100252		17
709	Antibodies and Vaccines Target RBD of SARS-CoV-2. 2021 , 8, 671633		32
708	Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. <i>Cell</i> , 2021 , 184, 2316-2331.e15	56.2	168
707	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. <i>Cell</i> , 2021 , 184, 1804-1820.e16	56.2	149
706	Pourquoi tant d'anticorps monoclonaux en thérapie et comment appréhender cette profusion ?. 2021 , 2021, 40-47		
705	A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. 2021 , 12, 647934		18
704	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. 2021 , 20, 88		12
703	Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants. 2021 , 290, 114084		1

702	Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2. 2021,	4
701	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. 2021, 2, 100230	40
700	Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. 2021, 7, 757-767	24
699	The Three Pillars of COVID-19 Convalescent Plasma Therapy. 2021, 11,	10
698	A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model.	3
697	The Mechanisms and Animal Models of SARS-CoV-2 Infection. 2021, 9, 578825	13
696	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. 2021, 60, 1459-1484	17
695	Antibody Responses in COVID-19: A Review. 2021, 12, 633184	32
694	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. 2021,	13
693	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice.	2
692	TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. 2021, 18, 627-630	13
691	Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. 2021, 35, 109173	14
690	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. 2021, 7,	40
689	SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. 2021, 595, 421-425	197
688	IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. 2021, 6,	7
687	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. 2021, 373, 818-823	148
686	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. 2021,	19
685	Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients. 2021, 12, 659018	4

684	SARS-CoV-2 cell entry and targeted antiviral development. 2021 , 11, 3879-3879	5
683	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. 2021 , 29, 806-818.e6	24
682	Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. 2021 , 8, 670815	5
681	Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets. 2021 , 34, 510-521	0
680	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. 2021 , 35, 109179	20
679	A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. 2021 , 12, 2623	25
678	Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. 2021 , 29, 819-833.e7	215
677	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. 2021 , 7, 1001-1008	8
676	Engineered Ultra-High Affinity Synthetic Antibodies for SARS-CoV-2 Neutralization and Detection. 2021 , 433, 166956	4
675	Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies.	2
674	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. 2021 , 12, 662909	
673	Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq. 2021 , 6, 195	10
672	Potent and Persistent Antibody Response in COVID-19 Recovered Patients. 2021 , 12, 659041	2
671	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. 2021 , 10,	11
670	Current Strategies of Antiviral Drug Discovery for COVID-19. 2021 , 8, 671263	24
669	Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. 2021 , 31, 732-741	47
668	Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins. 2021 , 11, 10475	2
667	Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies. 2021 , 13,	2

666	Global characterization of B cell receptor repertoire in COVID-19 patients by single-cell V(D)J sequencing. 2021 , 22,	6
665	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. 2021 ,	
664	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. 2021 , 35, 109109	7
663	Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. 2021 , 7,	19
662	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. 2021 , 15, 27	23
661	Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice. 2021 , 24, 102479	15
660	A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation. 2021 , 12, 2697	25
659	Mapping Potential Antigenic Drift Sites (PADS) on SARS-CoV-2 Spike in Continuous Epitope-Paratope Space. 2021 ,	
658	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.	1
657	Second-Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern.	
656	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. 2021 , 44, 392-400	5
655	Identification of Cross-Reactive CD8 T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants. 2021 ,	8
654	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. 2021 , 12, 3815	15
653	A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants.	2
652	Antimicrobial Peptides and Physical Activity: A Great Hope against COVID 19. 2021 , 9,	4
651	Structures of synthetic nanobody-SARS-CoV-2-RBD complexes reveal distinct sites of interaction and recognition of variants. 2021 ,	
650	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. 2021 , 12, 3661	14
649	Polysulfate hemmen durch elektrostatische Wechselwirkungen die SARS-CoV-2-Infektion**. 2021 , 133, 16005-16014	

648	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	37
647	IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers. 2021 , 6, e0017021	4
646	Structure-based Design of a Specific, Homogeneous Luminescence Enzyme Reporter Assay for SARS-CoV-2. 2021 , 433, 166983	0
645	Is SARS-CoV-2 Neutralized More Effectively by IgM and IgA than IgG Having the Same Fab Region?. 2021 , 10,	2
644	Single-Cell Transcriptomics Reveals the Cellular Heterogeneity of Cardiovascular Diseases. 2021 , 8, 643519	2
643	Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant. 2021 , 2, 442	3
642	Advances in Neutralization Assays for SARS-CoV-2. 2021 , 94, e13088	10
641	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. 2021 , 12, 697074	5
640	Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses. 2021 , 12, 678570	9
639	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. 2021 , 9, 622-642	121
638	Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. 2021 ,	0
637	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. 2021 , 6, 233	60
636	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. 2021 , 12, 3802	28
635	SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. 2021 , 11, 676451	6
634	Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. 2021 , 12, 691715	17
633	Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions*. 2021 , 60, 15870-15878	14
632	SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. 2021 , 54, 1304-1319.e9	41
631	Nanotraps for the containment and clearance of SARS-CoV-2. 2021 , 4, 2059-2082	14

630	Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. 2021 , 22, 851-864		23
629	Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. <i>Cell</i> , 2021 , 184, 3192-3204.e16	56.2	32
628	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. 2021 , 12, 687869		9
627	Recent advances in antibody-based immunotherapy strategies for COVID-19. 2021 , 122, 1389-1412		9
626	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021 , 184, 3086-3108	56.2	108
625	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. 2021 , 595, 426-431		247
624	SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells. 2021 , 7, e07147		4
623	Detection and Neutralization of SARS-CoV-2 Using Non-conventional Variable Lymphocyte Receptor Antibodies of the Evolutionarily Distant Sea Lamprey. 2021 , 12, 659071		1
622	The serological diversity of serum IgG/IgA/IgM against the SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan.		2
621	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021 , 184, 3205-3221.e24	36.2	34
620	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. 2021 , 207, 878-887		8
619	Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. 2021 , 7, 57		10
618	SARS-CoV-2 receptor-binding mutations and antibody contact sites. 2021 , 4, 149-158		5
617	Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. 2021 , 6, 13		1
616	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. 2021 , 36, 109452		25
615	Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects.		5
614	Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak. 2021 , 37, e3186		4
613	Pharmacokinetic profiles of a SARS-COV-2 neutralizing antibody BD-604 in cynomolgus monkeys. 2021 , 13, 1727-1734		1

612 The impact of hypoxia on B cells in COVID-19.

611 Antibody and B cell responses to SARS-CoV-2 infection and vaccination. **2021**, 29, 1063-1075 30

610 Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization. **2021**, 10, 0

609 Mutation-induced Changes in the Receptor-binding Interface of the SARS-CoV-2 Delta Variant B.1.617.2 and Implications for Immune Evasion.

608 Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. **2021**, 7, 1368-1380 5

607 A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. **2021**, 13, 21

606 Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. **2021**, 12, 4196 106

605 Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. **2021**, 19, 169 14

604 Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. **2021**, 36, 109385 5

603 Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers. **2021**, 6, 11

602 Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike. **2021**, 3

601 Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. **2021**, 36, 109353 41

600 Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. **2021**, 7, 2546-2564 8

599 Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates. **2021**, 1, 100003 3

598 Rapid, label-free, and sensitive point-of-care testing of anti-SARS-CoV-2 IgM/IgG using all-fiber Fresnel reflection microfluidic biosensor. **2021**, 188, 261 4

597 Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip. **2021**, 188, 262 11

596 Phenotypic determinism and stochasticity in antibody repertoires of clonally expanded plasma cells. 1

595 Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. 4

594	Evaluation of kinetics and thermodynamics of interaction between immobilized SARS-CoV-2 nucleoprotein and specific antibodies by total internal reflection ellipsometry. 2021 , 594, 195-203	18
593	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. 2021 , 36, 109433	25
592	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021 , 184, 3936-3948.e10	56.2 99
591	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. 2021 , 31, 1011-1023	18
590	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. 2021 , 12, 4210	23
589	A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. 2021 , 12, 4635	15
588	A Microfluidic Chip for Screening and Sequencing of Monoclonal Antibody at a Single-Cell Level. 2021 , 93, 10099-10105	1
587	Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility. 2021 , 433, 167051	28
586	Monocytes and Macrophages in COVID-19. 2021 , 12, 720109	39
585	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. 2021 , 54, 1611-1621.e5	85
584	Induction of cross-reactive antibody responses against the RBD domain of the spike protein of SARS-CoV-2 by commensal microbiota.	1
583	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. 2021 , 36, 109604	22
582	Rational optimization of a human neutralizing antibody of SARS-CoV-2. 2021 , 135, 104550	3
581	A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. 2021 , 12, 5000	7
580	Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. 2021 , 12, 723585	3
579	Deep geometric representations for modeling effects of mutations on protein-protein binding affinity. 2021 , 17, e1009284	6
578	Longitudinal analysis of antibody decay in convalescent COVID-19 patients. 2021 , 11, 16796	9
577	Immunity to SARS-CoV-2 induced by infection or vaccination. 2021 ,	24

576	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021 , 184, 4203-4219.e32	56.2	89
575	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. 2021 ,		25
574	Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. 2021 , 7, 67		10
573	Mutations in SARS-CoV-2 Variants Modulate the Microscopic Dynamics of Neutralizing Antibodies.		
572	Biomarkers and Immune Repertoire Metrics Identified by Peripheral Blood Transcriptomic Sequencing Reveal the Pathogenesis of COVID-19. 2021 , 12, 677025		0
571	Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. 2021 , 8, 100098		5
570	Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants.		
569	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. 2021 , 9,		6
568	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. 2021 , 6,		10
567	Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19. 2021 , 9,		1
566	The impact of high-resolution structural data on stemming the COVID-19 pandemic. 2021 , 49, 127-138		1
565	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. 2021 , 6, 317		17
564	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies.		7
563	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. 2021 , 54, 1853-1868.e7		83
562	Limited variation between SARS-CoV-2-infected individuals in domain specificity and relative potency of the antibody response against the spike glycoprotein.		
561	N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation. 2021 , 9, 697035		11
560	RAPID: A Rep-Seq Dataset Analysis Platform With an Integrated Antibody Database. 2021 , 12, 717496		2
559	Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19. 2021 , 15, 205-210		5

558	A broadly neutralizing biparatopic Nanobody protects mice from lethal challenge with SARS-CoV-2 variants of concern.	1
557	Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants. 2021 , 17, e1009286	27
556	Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization. 2021 , 7, 64	3
555	Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. 2021 , 11,	7
554	Explainable DCNN based chest X-ray image analysis and classification for COVID-19 pneumonia detection. 2021 , 11, 16071	1
553	Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates. 2021 , 12, 626553	18
552	Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals. 2021 , 6, e0057121	1
551	Modeling Coronavirus Spike Protein Dynamics: Implications for Immunogenicity and Immune Escape.	
550	Exploring COVID-19 at the single-cell level. 2021 , Publish Ahead of Print,	
549	The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications. 2021 , 35, 687-702	0
548	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. 2021 , 54, 2399-2416.e6	30
547	Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. 2021 , 31, 1130-1133	18
546	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. 2021 , 29, 951-962.e3	13
545	Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells. 2021 , 6, 113	5
544	SAS: A Platform of Spike Antigenicity for SARS-CoV-2. 2021 , 9, 713188	1
543	No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults.	
542	A thermostable oral SARS-CoV-2 vaccine induces mucosal and protective immunity.	1
541	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. 2021 ,	14

540	A surrogate cell-based SARS-CoV-2 spike blocking assay. 2021 , 51, 2665-2676	2
539	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. 2021 , 36, 109760	29
538	Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. 2021 , 297, 101202	7
537	Synthetic Neutralizing Peptides Inhibit the Host Cell Binding of Spike Protein and Block Infection of SARS-CoV-2. 2021 , 64, 14887-14894	1
536	Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants. 2021 , 31, 1126-1129	3
535	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques.	
534	Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display. 2021 , ,	
533	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. 2021 , 6, 1233-1244	72
532	Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. 2021 , 12, e0239521	5
531	NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment. 2021 , 133, 25632	0
530	SCIGA: Software for large-scale, single-cell immunoglobulin repertoire analysis. 2021 , 10,	
529	A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2.	19
528	An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice.	4
527	D614G mutation in the SARS-CoV-2 spike protein enhances viral fitness by desensitizing it to temperature-dependent denaturation. 2021 , 297, 101238	11
526	Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF- α inhibitors.	1
525	Characterization of SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor.	2
524	Understanding the pathogenesis of infectious diseases by single-cell RNA sequencing. 2021 , 8, 208-222	2
523	Structure-activity relationships of B.1.617 and other SARS-CoV-2 spike variants.	6

522	Structural biology of SARS-CoV-2 and implications for therapeutic development. 2021 , 19, 685-700	38
521	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. 2021 , 433, 167177	10
520	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. 2021 , 12, 5469	23
519	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. 2021 , 12, 708848	4
518	NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment. 2021 , 60, 25428-25435	3
517	SARS-CoV-2 Spike protein enhances ACE2 expression via Facilitating Interferon effects in bronchial epithelium. 2021 , 237, 33-41	4
516	Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky. 2021 , 11, 18285	0
515	Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. 2021 , 37, 109771	20
514	Increased neutralization of SARS-CoV-2 Delta variant by nanobody (Nb22) and the structural basis.	
513	Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. 2021 , 1-21	0
512	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. 2021 ,	65
511	Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody. 2021 , 12, 751584	5
510	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. 2021 , 194, 105147	2
509	Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus. 2021 , 99, 108020	2
508	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. 2021 , 297, 101127	2
507	Cell entry by SARS-CoV-2. 2021 , 46, 848-860	34
506	Meta-analysis of single-cell RNA-seq data reveals phenotypic switching of immune cells in severe COVID-19 patients. 2021 , 137, 104792	3
505	Rapid and quantitative detection of SARS-CoV-2 IgG antibody in serum using optofluidic point-of-care testing fluorescence biosensor. 2021 , 235, 122800	3

504	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. 2021 , 109, 108035	12
503	Computational insights into the membrane fusion mechanism of SARS-CoV-2 at the cellular level. 2021 , 19, 5019-5028	0
502	Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain. 2021 ,	0
501	Single Cell Mass Spectrometry with a Robotic Micromanipulation System for Cell Metabolite Analysis. 2021 , PP,	2
500	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. 2021 ,	54
499	Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. 2021 , 63, 103197	11
498	The impact of Spike mutations on SARS-CoV-2 neutralization.	22
497	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. 2021 , 31, 272-290	102
496	Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. 2021 ,	21
495	Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. 2021 , 19, 2806-2818	10
494	Pharmacotherapeutics of SARS-CoV-2 Infections. 2021 , 16, 12-37	3
493	Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. 2021 , 21, e8	2
492	Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative.	
491	Development and application of therapeutic antibodies against COVID-19. 2021 , 17, 1486-1496	16
490	Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2. 2021 , 22, 714-725	12
489	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. 2021 , 2, 1	6
488	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection. 2021 , 296, 100346	9
487	Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. 2021 , 12, 250	45

486	Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. 2021 , 5, 2001031	16
485	An Overview of the Crystallized Structures of the SARS-CoV-2. 2020 , 39, 600-618	17
484	Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. 2020 , 35, 713-724	7
483	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. 2021 , 590, 320-325	74
482	Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications. 2020 , 48, 2851-2863	2
481	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. 2021 , 218,	171
480	Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. 2020 , 3, 285-299	16
479	The development of neutralizing antibodies against SARS-CoV-2 and their common features. 2020 , 12, 980-986	5
478	Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. 2021 , 8, nwaa297	14
477	Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins.	24
476	A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. 2020 ,	9
475	Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity.	30
474	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. 2020 ,	30
473	An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.	19
472	A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds.	2
471	SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.	8
470	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020 ,	35
469	Structural basis of a public antibody response to SARS-CoV-2. 2020 ,	14

468	A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection.	16
467	Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma.	5
466	Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike. 2020,	25
465	Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. 2020,	33
464	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. 2020,	4
463	Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.	11
462	Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains. 2020,	28
461	Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19. 2020,	19
460	Natural killer cell activation related to clinical outcome of COVID-19.	5
459	A single-dose live-attenuated YF17D-vectored SARS-CoV2 vaccine candidate.	11
458	Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2. 2020,	4
457	Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency.	6
456	Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.	146
455	Dynamics of B-cell repertoires and emergence of cross-reactive responses in COVID-19 patients with different disease severity. 2021,	2
454	Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization. 2020,	15
453	A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection.	5
452	Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles.	3
451	SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.	27

450	Virus-free and live-cell visualizing SARS-CoV-2 cell entry for studies of neutralizing antibodies and compound inhibitors.	1
449	An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. 2020,	8
448	Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries.	1
447	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.	1
446	SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses.	11
445	REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters.	15
444	Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. 2020,	13
443	Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. 2020,	6
442	Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients.	2
441	An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation. 2020,	20
440	A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential.	15
439	Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. 2020,	2
438	A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model. 2020,	15
437	A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD.	8
436	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. 2020,	3
435	Chest X-ray image analysis and classification for COVID-19 pneumonia detection using Deep CNN.	2
434	Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2. 2020,	10
433	The influence of major S protein mutations of SARS-CoV-2 on the potential B cell epitopes.	1

432	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans.	12
431	Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies. 2020,	18
430	Engineered Trimeric ACE2 Binds and Locks 3-Spike Protein to Potently Inhibit SARS-CoVs and Mutants.	2
429	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.	8
428	SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells.	1
427	The dichotomous and incomplete adaptive immunity in COVID-19.	1
426	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro. 2020,	15
425	Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. 2020,	32
424	A COVID-19 antibody curbs SARS-CoV-2 nucleocapsid protein-induced complement hyper-activation.	2
423	A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD.	3
422	Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.	1
421	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. 2021,	8
420	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection. 2020,	21
419	High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamsters.	10
418	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. 2020,	2
417	NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response.	4
416	A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.	1
415	The quantitative landscape of the neutralizing antibody response to SARS-CoV-2.	2

414	A potent SARS-CoV-2 neutralizing human monoclonal antibody that reduces viral burden and disease severity in Syrian hamsters. 2020,	2
413	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.	1
412	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19.	2
411	Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors. 2020,	5
410	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.	2
409	Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers.	10
408	Structure, Dynamics, Receptor Binding, and Antibody Binding of Fully-glycosylated Full-length SARS-CoV-2 Spike Protein in a Viral Membrane.	1
407	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. 2020,	8
406	Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants.	3
405	Evolution of Antibody Immunity to SARS-CoV-2. 2021,	43
404	Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades ago.	6
403	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.	1
402	Analysis of SARS-CoV-2 spike glycosylation reveals shedding of a vaccine candidate.	10
401	Recurrent mutations in SARS-CoV-2 genomes isolated from mink point to rapid host-adaptation.	31
400	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. 2021,	4
399	N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation.	7
398	Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2.	3
397	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry. 2020,	6

396	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations.	8
395	Identification of four linear B-cell epitopes on the SARS-CoV-2 spike protein able to elicit neutralizing antibodies.	2
394	Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants.	15
393	In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum.	1
392	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma. 2020 ,	29
391	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection. 2020 ,	29
390	Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients.	1
389	Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence.	3
388	Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro.	1
387	Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. 2020 , 130, 6588-6599	50
386	CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention. 2020 , 15, e0239566	11
385	Antibody response to SARS-CoV-2 infection in humans: A systematic review. 2020 , 15, e0244126	130
384	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. 2020 , 16, e1009089	33
383	SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. 2020 ,	12
382	Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2. 2020 ,	8
381	Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses.	1
380	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. 2020 , 9,	784
379	Comparing Immune Responses to Inactivated Vaccines Against SARS-CoV-2 Between People Living With HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.	

378	Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage. 2021 , 224, 1861-1872	1
377	Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS-CoV-2 RNA. 2021 ,	1
376	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. 2021 , 13, 164	10
375	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. 2021 , 13,	1
374	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. 2021 , 13,	3
373	The herd immunity to SARS-CoV-2 among the population of the Nizhny Novgorod region amid the COVID-19 epidemic. 2021 , 13, 30-39	0
372	A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. 2021 , 12, e0247321	11
371	Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid. 2021 , 340, 114-124	1
370	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration. 2021 , 37, 109869	13
369	Structure-guided antibody cocktail for prevention and treatment of COVID-19. 2021 , 17, e1009704	6
368	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. 2021 , 35, e21970	4
367	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. 2021 ,	1
366	Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. 2021 , 13, e14544	1
365	Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects. 2021 , JVI0111021	7
364	Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. 2021 , 37, 109928	21
363	Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. 2021 , 6, 369	3
362	Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. 2021 , 9, e0135221	2
361	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 2021 , 12, 6097	15

360	SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury.	1
359	Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. 2021 , 4, 1196	16
358	Nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants.	1
357	Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2 despite Spike-dependent modulation of phagocytosis.	3
356	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. 2021 , 7, 96	5
355	Effective chimeric antigen receptor T cells against SARS-CoV-2. 2021 , 24, 103295	5
354	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. 2021 , 7, eabj3107	7
353	Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies. 2021 , 41, 1065	0
352	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. 2021 , 37, 109881	6
351	Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection.	2
350	Stereotypic Neutralizing VH Clonotypes Against SARS-CoV-2 RBD in COVID-19 Patients and the Healthy Population.	4
349	Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.	4
348	Antibody response to SARS-CoV-2 infection in humans: a systematic review.	5
347	Rational Design of SARS-CoV-2 Spike Glycoproteins To Increase Immunogenicity By T Cell Epitope Engineering. 2020 ,	3
346	Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike. 2020 ,	1
345	SARS-Cov-2-, HIV-1-, Ebola-neutralizing and anti-PD1 clones are predisposed.	1
344	A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain core.	1
343	Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and Beyond. 2021 ,	8

342	Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants. 2021 , 39, 7001-7011	4
341	Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago. 2021 , e2102181	6
340	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. 2021 , 22, 1503-1514	12
339	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein using mRNA Display.	
338	. 2020 , 192, E1776-E1782	
337	Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products in vitro.	
336	Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine.	1
335	Dynamics of B-Cell Repertoires and Emergence of Cross-Reactive Responses in COVID-19 Patients with Different Disease Severity.	1
334	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. 2020 , 3639618	3
333	Severe Acute Respiratory Syndrome Coronavirus 2 Antigens as Targets of Antibody Responses.. 2022 , 42, 97-109	
332	Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies.	
331	Single B cell technologies for monoclonal antibody discovery. 2021 , 42, 1143-1158	6
330	Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients. 2021 , 83, 119-119	3
329	An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2. 2021 , 12, 752739	7
328	Severity and inpatient mortality of COVID-19 pneumonia from Beta variant infection: a clinical cohort study in Cape Town, South Africa.	0
327	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. 2021 , 12, 6304	15
326	A high-throughput, automated, cell-free expression and screening platform for antibody discovery.	0
325	Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies. 2021 , 10,	2

324	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. 2021 , 6, 378	5
323	The answer lies in the energy: how simple atomistic molecular dynamics simulations may hold the key to epitope prediction on the fully glycosylated SARS-CoV-2 spike protein.	1
322	Single-cell transcriptomic analyses define distinct peripheral B cell subsets and discrete development pathways.	0
321	Large-scale single-cell analysis reveals critical immune characteristics of COVID-19 patients.	0
320	Editorial: The battle for survival between severe acute respiratory syndrome coronavirus 2 and human beings. 2020 , 15, 325-327	
319	CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention.	0
318	Quantitative measurement of IgG to SARS-CoV-2 proteins using ImmunoCAP. 2020 ,	
317	Trimeric SARS-CoV-2 Spike proteins produced from CHO-cells in bioreactors are high quality antigens.	1
316	[Immunity against SARS-CoV-2: walking to the vaccination]. 2020 , 33, 392-398	1
315	A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. 2021 , e2103240	3
314	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. 2021 , 1-30	7
313	Single-Cell Genomics: Enabling the Functional Elucidation of Infectious Diseases in Multi-Cell Genomes. 2021 , 10,	
312	The glycosylation in SARS-CoV-2 and its receptor ACE2. 2021 , 6, 396	13
311	Overview of Neutralizing Antibodies and Their Potential in COVID-19.. 2021 , 9,	5
310	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. 2021 , 101533	11
309	Antibody cocktail effective against variants of SARS-CoV-2. 2021 , 28, 80	6
308	Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor- α inhibitors. 2021 ,	8
307	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. 2021 , e0297521	7

306	Possibility of exosome-based coronavirus disease 2019 vaccine (Review). 2022 , 25,	5
305	B cell clonal expansion is correlated with antigen-specificity in young but not old mice.	1
304	A large-scale systematic survey of SARS-CoV-2 antibodies reveals recurring molecular features. 2021 ,	3
303	Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape. 2021 ,	5
302	A second functional furin site in the SARS-CoV-2 spike protein. 2021 , 1-35	3
301	Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape. 2021 ,	9
300	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. 2021 ,	5
299	Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics?. 2021 , e2314	5
298	ScRNA-Seq study of neutrophils reveals vast heterogeneity and breadth of inflammatory responses in severe COVID-19 patients.	
297	Current strategies for detecting functional convergence across B-cell receptor repertoires. 2021 , 13, 1996732	2
296	Konjunktivitis (engl. conjunctivitis). 2021 , 125-168	
295	Structural basis of Omicron neutralization by affinity-matured public antibodies.	3
294	Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.. 2021 , 141, 287-296	0
293	Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review.. 2022 , 640, 114546	2
292	Functional nucleic acids as modular components against SARS-CoV-2: From diagnosis to therapeutics.. 2021 , 201, 113944	0
291	Complex biological questions being addressed using single cell sequencing technologies.. 2021 ,	1
290	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.	30
289	Single-cell immunology of SARS-CoV-2 infection.. 2021 ,	5

288	Quantitative measurement of IgG to SARS-CoV-2 antigens using monoclonal antibody-based enzyme-linked immunosorbent assays.. 2022 , 11, e1369	1
287	Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy.. 2022 , 1	0
286	SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display.. 2021 , 110242	1
285	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.. 2022 , 110368	10
284	Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.. 2022 , 14,	2
283	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.. 2022 ,	89
282	Single-Cell Analysis Reveals the Immune Characteristics of Myeloid Cells and Memory T Cells in Recovered COVID-19 Patients With Different Severities.. 2021 , 12, 781432	1
281	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies.	0
280	A novel magnetophoretic-based device for magnetometry and separation of single magnetic particles and magnetized cells.. 2022 ,	0
279	The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro.. 2022 ,	1
278	A spatial and cellular distribution of rabies virus infection in the mouse brain revealed by fMOST and single-cell RNA sequencing.. 2022 , 12, e700	0
277	Unraveling B cell trajectories at single cell resolution.. 2022 ,	4
276	Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.. 2022 , e0267621	
275	Multiple sclerosis therapies differentially impact SARS-CoV-2 vaccine-induced antibody and T cell immunity and function.. 2022 ,	15
274	Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron.. <i>Cell</i> , 2022 ,	56.2 39
273	Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display.. 2022 , 38, 110348	2
272	Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2.. 2021 , 12, 808932	3
271	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies.. 2022 , 13, 462	3

270	Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).. 2022 , 60,	0
269	The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice.. 2022 , 15, 38	1
268	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.. 2022 , 29, 1	17
267	Longitudinal comparison of automated SARS-CoV-2 serology assays in assessing virus neutralization capacity in COVID-19 convalescent sera.. 2022 ,	1
266	Pandemic Strategies with Computational and Structural Biology against COVID-19: A Retrospective.. 2021 ,	2
265	Evaluation of Drug Repositioning by Molecular Docking of Pharmaceutical Resources to Identification of Potential SARS-CoV-2 Viral Inhibitors.	
264	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability.. 2022 ,	1
263	Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.. 2022 , 38, 110303	0
262	SARS-CoV-2 Infection and Lung Regeneration.. 2022 , e0018821	4
261	Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.. 2022 , 132,	0
260	Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.. 2022 , 76, 103818	3
259	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.. 2022 ,	1
258	Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.. 2021 , 53, 101199	0
257	Monoclonal Antibody Therapeutics for Infectious Diseases: Beyond Normal Human Immunoglobulin.	
256	A high-throughput single cell-based antibody discovery approach against the full-length SARS-CoV-2 spike protein suggests a lack of neutralizing antibodies targeting the highly conserved S2 domain.. 2022 ,	0
255	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.. 2022 , 14, eabi9215	15
254	An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.. <i>Cell</i> , 2022 , 185, 614-629.e21	56.2 7
253	Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice.. 2022 ,	6

252	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.. 2022 , 399, 665-676	43
251	BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19.	
250	Cryo-EM structure of the SARS-CoV-2 Omicron spike.. 2022 , 110428	12
249	Comprehensive Epitope Mapping of Broad Sarbecovirus Neutralizing Antibodies.	1
248	Magnetic Enrichment of SARS-CoV-2 Antigen-Binding B Cells for Analysis of Transcriptome and Antibody Repertoire. 2022 , 8, 23	0
247	SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine.. 2022 , 7, eabn8590	22
246	An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.. 2022 , 7, 44	1
245	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants.. 2021 , 12, 766821	5
244	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.. 2021 , 37, 110143	16
243	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding.. 2021 , 37, 110156	11
242	Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM.. 2021 , 12, 7345	13
241	Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography.. 2021 , 12, 7325	4
240	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.. 2021 ,	249
239	Deep dissection of the antiviral immune profile of patients with COVID-19.. 2021 , 4, 1389	3
238	A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. 2021 , 118,	4
237	Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern.. 2021 , e53865	6
236	The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters.. 2021 ,	17
235	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. 2021 , 10,	3

234	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. 2022 ,	0
233	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. 2022 , 205-226	
232	Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: a dynamic insight.. 2022 ,	1
231	Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains.. 2022 ,	
230	Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. 2022 , 14, 2031483	2
229	A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity.. 2022 , 13, 837443	3
228	Analysis of B cell receptor repertoires reveals key signatures of systemic B cell response after SARS-CoV-2 infection. 2021 , JVI0160021	2
227	Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies.. 2022 , 13, 871	13
226	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.. 2022 , 18, e1010260	12
225	Innate Immune Response in SARS-CoV-2 Infection.. 2022 , 10,	0
224	Omicron Spike protein has a positive electrostatic surface that promotes ACE2 recognition and antibody escape.	0
223	Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. 2022 , 2, 123-131	2
222	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.. <i>Cell</i> , 2022 ,	56.2 3
221	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22).. 2022 , 13, 865401	0
220	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization.. 2022 , 13, 836232	0
219	Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization.. 2022 , 119, e2122954119	1
218	Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.. 2022 , e0009922	3
217	Structural basis of nanobodies neutralizing SARS-CoV-2 variants.. 2022 ,	0

216	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.. 2022 , 13, 1638	2
215	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions.. 2022 , 25, 103939	2
214	No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults.. 2022 , 103951	1
213	Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants.. 2022 ,	1
212	Detection, prevention and treatment of COVID-19 and opportunities for nanobiotechnology. 20200181	3
211	A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2.. 2022 ,	2
210	The impact of hypoxia on B cells in COVID-19.. 2022 , 77, 103878	3
209	Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine.. 2022 ,	
208	CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses.. 2022 ,	2
207	Unbinding of hACE2 and inhibitors from the receptor binding domain of SARS-CoV-2 spike protein.. 2022 , 1-20	
206	Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern.. 2022 , 5,	0
205	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants.. 2022 , 110558	1
204	Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.. 2022 , e0181421	1
203	Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.. 2022 ,	2
202	AbAdapt: An adaptive approach to predicting antibody-antigen complex structures from sequence.	0
201	Circular RNA vaccines against SARS-CoV-2 and emerging variants.. <i>Cell</i> , 2022 ,	56.2 21
200	Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2.	0
199	Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents.. 2022 , 10,	

198	Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization.. 2022 , 87, 319-330	
197	Delineating antibody escape from Omicron variants.	2
196	Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design.. 2022 , e2347	1
195	Upstream cell culture process characterization and in-process control strategy development at pandemic speed.. 2022 , 14, 2060724	1
194	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.. 2022 , 200, 105290	1
193	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies.. 2022 , 258, 126993	3
192	Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.. 2022 , 201, 105297	1
191	Computational Electrostatics Predict Variations in SARS-CoV-2 Spike and Human ACE2 Interactions. 2021 ,	
190	Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. 2022 , 2,	1
189	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617.. 2021 ,	20
188	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. 2021 , 18, e1003868	2
187	Modeling and predicting the overlap of B- and T-cell receptor repertoires in healthy and SARS-CoV-2 infected individuals.	0
186	Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells.. 2022 , 14, 2005507	1
185	Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant.	0
184	A recurring YYDRxG pattern in broadly neutralizing antibodies to a conserved site on SARS-CoV-2, variants of concern, and related viruses.	5
183	Viral population genomics reveals host and infectivity impact on SARS-CoV-2 adaptive landscape.	0
182	An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.	0
181	Dual UMIs and Dual Barcodes With Minimal PCR Amplification Removes Artifacts and Acquires Accurate Antibody Repertoire.. 2021 , 12, 778298	

- 180 Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods.. **2021**, 41, 1052 4
- 179 Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases.. **2022**, 2410, 229-263 o
- 178 A high potent synthetic nanobody with broad-spectrum activity neutralizes SARS-Cov-2 virus and Omicron variant through a unique binding mode.
- 177 Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.. **2022**, 1-11 1
- 176 BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.. **2022**, 13, 797918
- 175 Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.1 and BA.2 variants and their mouse origins. o
- 174 Molecularly Imprinted Polymer Nanoparticles Enable Rapid, Reliable, and Robust Point-of-Care Thermal Detection of SARS-CoV-2.. **2022**, 4
- 173 Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing.. **2022**, 108, 108767 o
- 172 DataSheet_1.pdf. **2020**,
- 171 Image_1.tif. **2020**,
- 170 Image_2.tif. **2020**,
- 169 DataSheet_1.docx. **2020**,
- 168 Table_1.docx. **2020**,
- 167 Table_1.DOC. **2020**,
- 166 The relationship between IgG and IgM levels and severity of symptoms in COVID-19 patients confirmed by rapid antigen test.. **2021**, 14, 790-796 o
- 165 [Applications of separation technology in novel coronavirus research, epidemic prevention and detection]. **2021**, 39, 679-685
- 164 SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses.. **2022**, 20, 2042-2056 o
- 163 Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies.. **2022**, o

162	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.. 2022 ,	3
161	Phenotypic determinism and stochasticity in antibody repertoires of clonally expanded plasma cells.. 2022 , 119, e2113766119	0
160	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.	9
159	AbSE Workflow: Rapid Identification of the Coding Sequence and Linear Epitope of the Monoclonal Antibody at the Single-cell Level.. 2022 , 11, 1856-1864	
158	Antibodies induced by ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1.. 2022 , eabo3425	2
157	Antibody-Mediated Neutralization of SARS-CoV-2. 2022 ,	5
156	Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies. 2022 , 110905	0
155	Point Mutations in SARS-CoV-2 Variants Induce Long-Range Dynamical Perturbations in Neutralizing Antibodies.	1
154	Peptide derived nanobody inhibits entry of SARS-CoV-2 variants.	
153	Shared N417-dependent epitope on the SARS-CoV-2 Omicron, Beta and Delta-plus variants.	0
152	Animal models for studying coronavirus infections and developing antiviral agents and vaccines. 2022 , 203, 105345	1
151	Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein. 2022 , 59, 107986	0
150	COVID-19-Current Therapeutical Approaches and Future Perspectives. 2022 , 10, 1053	1
149	The Undesirable Effects and Impacts of Ice Contamination Experienced in the Cryo-Electron Tomography Workflow and Available Solutions. 2022 , 30, 30-35	
148	Protective neutralizing epitopes in SARS-CoV-2.	3
147	Computational epitope mapping of class I fusion proteins using Bayes classification.	
146	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages.	
145	Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron 'BA.2 variant compared to BA.1 and their possible mouse origins.	5

144	Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics. 2022 , 17, e0267796	0
143	Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 Spike interaction with hACE2. 2022 , 100252	1
142	Omicron Spike Protein Has a Positive Electrostatic Surface That Promotes ACE2 Recognition and Antibody Escape. 2,	0
141	Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2.	
140	Atlas of currently-available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. 2022 ,	2
139	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.	85
138	Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. 2022 , 219,	3
137	Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. 2022 , 7, 1063-1074	4
136	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition.	1
135	Identification and Mechanistic Basis of non-ACE2 Blocking Neutralizing Antibodies from COVID-19 Patients with Deep RNA Sequencing and Molecular Dynamics Simulations.	
134	Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. 2022 , 13, 6064-6073	2
133	Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.	0
132	The humoral response and antibodies against SARS-CoV-2 infection. 2022 , 23, 1008-1020	2
131	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. 2022 , 5,	1
130	A new strategy: identification of specific antibodies for neutralizing epitope on SARS-CoV-2 S protein by LC-MS/MS combined with immune repertoire. 2022 , 3,	
129	Predictive Risk Factors at Admission and a Burning Point During Hospitalization Serve as Sequential Alerts for Critical Illness in Patients With COVID-19. 9,	
128	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. 2022 ,	0
127	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. 2022 ,	3

126	Protein Adsorption Loss-The Bottleneck of Single-Cell Proteomics.	1
125	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. 2022 , 219,	0
124	SARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites. 2022 , 2022, 1-14	1
123	Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review. 2022 , 20,	0
122	Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.	6
121	Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.	1
120	Delineating COVID-19 immunological features using single-cell RNA sequencing. 2022 , 100289	1
119	Neutralizing antibody evasion and receptor binding features of SARS-CoV-2 Omicron BA.2.75.	2
118	Modern antiviral biomedical cell products and their applications for COVID-19 therapy. 2022 , 21, 19-32	
117	Immune Evasion by the Highly Mutated SARS-CoV-2 Omicron Variant. Volume 15, 4013-4027	0
116	Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains. 2022 , 104798	
115	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. 2022 , 23, 8485	1
114	Decoding the Effects of Spike Receptor Binding Domain Mutations on Antibody Escape Abilities of Omicron Variants.	
113	Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron. 2022 , 5,	1
112	Publication trends of research on COVID-19 and host immune response: A bibliometric analysis. 10,	1
111	Global patterns of antigen receptor repertoire disruption across adaptive immune compartments in COVID-19. 2022 , 119,	0
110	Physical-chemical regulation of membrane receptors dynamics in viral invasion and immune defense. 2022 , 167800	0
109	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents.	0

- 108 Characterization of a broadly cross reactive tetravalent human monoclonal antibody, recognizing conformational epitopes in receptor binding domain of SARS-CoV-2. **2022**, 12,
- 107 Neutralization sensitivity of the SARS-CoV-2 Omicron BA.2.75 sublineage. o
- 106 The diversity of the glycan shield of sarbecoviruses closely related to SARS-CoV-2.
- 105 Epitopes mapped onto SARS-CoV-2 receptor-binding motif by five distinct human neutralising antibodies. 1-11
- 104 A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor. **2022**, 111335
- 103 Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients. 9, o
- 102 Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. **2022**, 14, 1
- 101 Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. **2022**, 8, 1
- 100 Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variants. **2022**, 627, 168-175 o
- 99 Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. **2022**, 4, 100054 o
- 98 Biophysical and structural characterizations of the effects of mutations on the structure–activity relationships of SARS-CoV-2 spike protein. **2022**, o
- 97 Antibody-mediated immunity to SARS-CoV-2 spike. **2022**, 1-69 o
- 96 Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. **2022**, 12, o
- 95 Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. 13, o
- 94 Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein. **2022**, 23, 10904 o
- 93 Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. 13, o
- 92 A study protocol to prepare an RBD protein for vaccine against COVID-19. 10, 943 o
- 91 Single-cell analysis of the adaptive immune response to SARS-CoV-2 infection and vaccination. 13, 1

90	Engineering recombinantly expressed lectin-based antiviral agents. 12,	0
89	Spatial- and Valence-Matched Neutralizing DNA Nanostructure Blocks Wild-Type SARS-CoV-2 and Omicron Variant Infection. 2022 , 16, 15310-15317	1
88	Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V(D)J sequencing. 13,	1
87	Different T-cell and B-cell repertoire elicited by the SARS-CoV-2 inactivated vaccine and S1 subunit vaccine in rhesus macaques.	0
86	A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode. 2022 , 20,	0
85	The global landscape of approved antibody therapies. 2022 , 5, 233-257	0
84	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. 2022 , 105193	1
83	Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. 2022 , 8,	0
82	Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. 2022 ,	5
81	Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets..	0
80	A novel plasma proteomic-based model for predicting liver fibrosis in HIV/HBV co-infected adults.	0
79	Characteristics of animal models for COVID-19. 2022 , 5, 401-409	2
78	AE-TPGG: a novel autoencoder-based approach for single-cell RNA-seq data imputation and dimensionality reduction. 2023 , 17,	0
77	Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection. 9,	0
76	Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants. 13,	0
75	Advances in antibody discovery from human BCR repertoires. 2,	0
74	Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants.	0
73	Recent approaches to mRNA vaccine delivery by lipid-based vectors prepared by continuous-flow microfluidic devices. 2022 , 14, 1561-1581	0

72	Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination. 2022 , 133, 102918	o
71	Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses.	o
70	Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques. 2022 ,	o
69	Heterogeneity of neutrophils and inflammatory responses in patients with COVID-19 and healthy controls. 13,	o
68	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. 13,	1
67	Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants. 2023 , 299, 102732	o
66	Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2. 2023 , 227, 896-902	o
65	A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. 2022 , 37, 1	o
64	Virus-like particle displaying SARS-CoV-2 receptor binding domain elicits neutralizing antibodies and is protective in a challenge model.	o
63	Microfluidic single-cell multiomics analysis. 20220034	1
62	Simultaneous detection of antibody responses to multiple SARS-CoV-2 antigens by a Western blot serological assay. 2022 , 106, 8183-8194	o
61	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?.	o
60	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. 10,	o
59	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. 2022 , 13,	o
58	Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.	o
57	Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD Target for Vaccine Development. 2023 , 11, 23	1
56	Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. 2023 , 11, 30	o
55	Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies. 2022 ,	o

54	Identification and mechanistic basis of non-ACE2 blocking neutralizing antibodies from COVID-19 patients with deep RNA sequencing and molecular dynamics simulations. 9,	0
53	Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. 2022 , 41, 111845	3
52	Neutralizing and enhancing antibodies against SARS-CoV-2. 2022 , 42,	0
51	Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofiling. 13,	0
50	Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2. 2022 , 10, 3274	1
49	Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods. 2022 , 18, e1010230	0
48	Single cell and immunity: Better understanding immune cell heterogeneities with single-cell sequencing. 2022 , 2,	0
47	Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. 2023 , 220,	1
46	Humoral immunity for durable control of SARS-CoV-2 and its variants. 2023 , 43,	0
45	COVID-19 surveillance in wastewater: An epidemiological tool for the monitoring of SARS-CoV-2. 12,	2
44	Single-cell omics: A new direction for functional genetic research in human diseases and animal models. 13,	0
43	An alpaca-derived nanobody recognizes a unique conserved epitope and retains potent activity against the SARS-CoV-2 omicron variant.	0
42	Safety and Effectiveness of SA58 Nasal Spray against COVID-19 Infection in Medical Personnel:An Open-label, Blank-controlled Study.	0
41	Single cell and immunity: Better understanding immune cell heterogeneities with single cell sequencing. 2023 , 13,	0
40	On Pre-trained Language Models for Antibody.	0
39	A cluster of broadly neutralizing IgG against BK polyomavirus in a repertoire dominated by IgM. 2023 , 6, e202201567	0
38	Epitope-directed anti-SARS-CoV -2 scFv engineered against the key spike protein region could block membrane fusion.	0
37	Applications of genetic engineering in COVID-19. 2023 , 219-237	0

- 36 State of the art in epitope mapping and opportunities in COVID-19. **2023**, 9, [100697](#) 
- 35 Quantitative analysis of high-throughput biological data. [100698](#) 
- 34 FIPRESCI: droplet microfluidics based combinatorial indexing for massive-scale 5'-end single-cell RNA sequencing. **2023**, 24, [100699](#) 
- 33 Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease. **2023**, 5, [100697](#) 
- 32 Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2-seropositive individuals. **2023**, 2, [100083](#) 
- 31 Generation of a single-cell B cell atlas of antibody repertoires and transcriptomes to identify signatures associated with antigen specificity. **2023**, 26, [106055](#) 
- 30 Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice. [100700](#) 
- 29 Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. **2023**, 15, [426](#) 
- 28 Single-cell RNA sequencing to identify cellular heterogeneity and targets in cardiovascular diseases: from bench to bedside. **2023**, 118, [100701](#) 
- 27 Development of animal models for emerging infectious diseases by breaking the barrier of species susceptibility to human pathogens. **2023**, 12, [100702](#) 
- 26 Advances in Research on COVID-19 Vaccination for People Living with HIV. **2022**, 2, [213-218](#) 
- 25 Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. **2023**, 95, [100703](#) 
- 24 Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern. **2023**, 95, [100704](#) 
- 23 Adenovirus Vaccine Containing Truncated SARS-CoV-2 Spike Protein S1 Subunit Leads to a Specific Immune Response in Mice. **2023**, 11, [429](#) 
- 22 SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial. **2023**, 57, [101832](#) 
- 21 Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. **2023**, 26, [106256](#) 
- 20 The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19. [100705](#) 
- 19 Modeling and predicting the overlap of B- and T-cell receptor repertoires in healthy and SARS-CoV-2 infected individuals. **2023**, 19, [e1010652](#) 

- 18 Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. **2023**, 14, ○
- 17 Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2. **2023**, 19, ○
- 16 Antibodies Targeting the Cell Wall Induce Protection against Virulent Mycobacterium bovis Infection. **2023**, 11, ○
- 15 An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations. **2023**, 117, 109934 ○
- 14 Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. **2023**, 133, ○
- 13 Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants. **2023**, 212, 105576 ○
- 12 Variants of SARS-CoV-2: Influences on the Vaccines Effectiveness and Possible Strategies to Overcome Their Consequences. **2023**, 59, 507 ○
- 11 Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses. 3, ○
- 10 Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study [Hohhot City, Inner Mongolia Autonomous Region, China, 2022. **2023**, 5, 218-222 ○
- 9 Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. **2023**, 24, 690-699 ○
- 8 An ancestral vaccine induces anti-Omicron antibodies by hypermutation. ○
- 7 Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies. 14, ○
- 6 Safety and Effectiveness of SA58 Nasal Spray against SARS-CoV-2 family transmission: an exploratory single-arm trial. ○
- 5 Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. **2023**, 26, 106540 ○
- 4 Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants. **2023**, 6, ○
- 3 Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses. ○
- 2 Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations. **2023**, 24, 7292 ○
- 1 Immune Imprinting and Implications for COVID-19. **2023**, 11, 875 ○

